Journal of the American Academy of Dermatology
Volume 60, Issue 4 , Pages 565-573 , April 2009

A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa

  • Robert A. Lee, MD, PhD

      Affiliations

    • Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • ,
  • Erica Dommasch, BA

      Affiliations

    • Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • ,
  • James Treat, MD

      Affiliations

    • Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • ,
  • Joslyn Sciacca-Kirby, MD

      Affiliations

    • Department of Dermatology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania
    • ,
  • Samuel Chachkin, MD

      Affiliations

    • Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • ,
  • Jennifer Williams, RN

      Affiliations

    • Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • ,
  • Daniel B. Shin, BA

      Affiliations

    • Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • ,
  • James J. Leyden, MD

      Affiliations

    • Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • Emeritus.
    • ,
  • Carmela Vittorio, MD

      Affiliations

    • Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • ,
  • Joel M. Gelfand, MD, MSCE

      Affiliations

    • Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • Corresponding Author InformationReprint requests: Joel M. Gelfand, MD, MSCE, 2 Maloney Bldg, 3600 Spruce St, Philadelphia, PA 19104.

,Accepted 20 November 2008.

References 

  1. Lee RA, Yoon A, Kist J. Hidradenitis suppurativa: an update. Adv Dermatol. 2007;23:289–306
  2. Jemec GB. Medical treatment of hidradenitis suppurativa. Expert Opin Pharmacother. 2004;5:1767–1770
  3. Jemec GB, Heidenheim M, Nielsen NH. Hidradenitis suppurativa–characteristics and consequences. Clin Exp Dermatol. 1996;21:419–423
  4. Revuz JE, Canoui-Poitrine P, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59:596–601
  5. Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35:191–194
  6. Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56:621–623
  7. Rosi YL, Lowe L, Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatolog Treat. 2005;16:58–61
  8. Trent JT, Kerdel FA. Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases. Dermatol Nurs. 2005;17:97–107
  9. LaDuca J. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases. Dermatol Clin. 2001;19:617–635
  10. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol. 2003;139:1540–1542
  11. Sullivan TP, Welsh E, Kerdel FA, Burdick AE, Kirsner RS. Infliximab for hidradenitis suppurativa. Br J Dermatol. 2003;149:1046–1049
  12. Elkjaer M, Dinesen L, Benazzato L, Rodriguez J, Løgager V, Munkholm P. Efficacy of infliximab treatment in patients with severe fistulizing hidradenitis. Journal of Crohn's and Colitis. 2008;2:241–245
  13. Antonucci A, Negosanti M, Negosanti L, Iozzo I, Varotti C. Acne inversa treated with infliximab: different outcomes in 2 patients. Acta Derm Venereol. 2008;88:274–275
  14. Usmani N, Clayton TH, Everett S, Goodfield MD. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol. 2007;32:204–205
  15. Yamauchi P. Adalimumab in the management of hidradenitis suppurativa. J Am Acad Dermatol. 2007;56:AB41
  16. Moschella S. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Int J Dermatol. 2007;46:1287–1291
  17. Fardet L, Dupuy A, Kerob D, Levy A, Allez M, Begon E, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 2007;56:624–628
  18. Fernández-Vozmediano JM, Armario-Hita JC. Infliximab for the treatment of hidradenitis suppurativa. Dermatology. 2007;215:41-1
  19. Henderson RL. Treatment of atypical hidradenitis suppurativa with the tumor necrosis factor receptor-Fc fusion protein etanercept (case reports). J Drugs Dermatol. 2006;5:1010–1011
  20. Zangrilli A, Esposito M, Mio G, Mazzotta A, Chimenti S. Long-term efficacy of etanercept in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2008;22:1260–1262
  21. Moul DK, Korman NJ. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol. 2006;142:1110–1112
  22. Scheinfeld N. Treatment of coincident seronegative arthritis and hidradenitis suppurativa with adalimumab. J Am Acad Dermatol. 2006;55:163–164
  23. Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus: surgical approach. In: Roenigk RK, Roenigk HH, eds. Dermatologic surgery: principles and practice. New York: Marcel Dekker Inc; 1996. pp. 623-645.
  24. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10
  25. Sachs DD, Gordon AT. Hidradenitis suppurativa of glands of Moll. Arch Ophthalmol. 1967;77:635–636
  26. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean?. J Investig Dermatol. 2005;125:659–664
  27. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, Petropoulou H, Baziaka F, Karagianni V, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol. 2008;158:567–572
  28. Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol. 2006;154:726–729
  29. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol. 2008;158:370–374
  30. Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol. 2008;58:443–446
  31. Thomson Reuters 2008: Nicomide drug monograph. The Physicians' Desk Reference Web site. Available at http://www.pdr.net/druginformation/FDAMonographsInfo.aspx?MonographID=1762. Accessed December 30, 2008

 Supported by an unrestricted grant from Amgen and grant K23AR051125 from the National Institute of Arthritis, Musculoskeletal, and Skin Diseases (Dr Gelfand).

 Disclosure: Dr Gelfand has received grant support from Amgen and Centocor, and is a consultant to Amgen, Abbott, Centocor, Genentech, and Astellas. Drs Lee, Treat, Sciacca-Kirby, Chachkin, Leyden, and Vittorio, Ms Dommasch, Ms Williams, and Mr Shin have no conflicts of interest to declare.

PII: S0190-9622(08)02470-5

doi: 10.1016/j.jaad.2008.11.898

Journal of the American Academy of Dermatology
Volume 60, Issue 4 , Pages 565-573 , April 2009

Article Tools

* Image Usage & Resolution